Navigation Links
New Test May Mean Faster Breast Cancer Treatment
Date:2/27/2009

Genetic analysis method can be used on all women with diagnosis, study says

FRIDAY, Feb. 27 (HealthDay News) -- A new genetic test that analyzes a set of 50 genes to identify four types of breast cancer could lead to quicker, more immediate treatment for patients, according to U.S. researchers who developed the test.

"Unlike a widely used genomic test that applies only to lymph-node-negative, estrogen-receptor-positive breast cancer, this new genomic test is broadly applicable for all women diagnosed with breast cancer," Dr. Matthew Ellis, of the Siteman Cancer Center at Washington University in St. Louis and Barnes-Jewish Hospital and a breast cancer specialist, said in a university news release.

Ellis and his colleagues analyzed the gene activity of more than 1,000 breast tumors and identified 50 genes that could be used to identify each of the four types of breast tumors -- luminal A, luminal B, HER2-enriched and basal-like. A genetic test called OncotypeDx, which is currently in wide use, doesn't identify all four tumor types, according to background information in the news release.

"Our test is the first to incorporate a molecular profile for the basal-like type breast cancers," Ellis said. "That's important because these breast cancers are arguably the most aggressive yet the most sensitive to chemotherapy. By identifying them, we can ensure they are treated adequately."

The new test also identifies what's often considered a fifth breast cancer type, known as normal-like. But the researchers discovered that, instead of being a fifth type of breast cancer, normal-like is an indicator that a breast tumor sample contains insufficient tumor cells to make a molecular diagnosis and that a new sample needs to be taken.

The researchers also said that the 50-gene test was highly accurate in predicting how 133 breast cancer patients would respond to chemotherapy. Luminal A was not sensitive to chemotherapy, which suggests that women with this good-prognosis type of breast cancer can forgo chemotherapy in favor of hormone-based therapy, they said. Among poor-prognosis types of breast cancer, they found that basal-like was the most sensitive to chemotherapy and luminal B the least sensitive.

The study was published online Feb. 9 in the Journal of Clinical Oncology.

More information

The American Cancer Society has more about breast cancer.



-- Robert Preidt



SOURCE: Washington University in St. Louis, news release, February 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Antidepressants Offer Faster Relief
2. Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation
3. Toward a faster prenatal test for Down syndrome
4. Regulatory Affairs Associates Gets New Drugs Tested Faster, Wins 2007 Innovation Michigan Award
5. RACE: a statewide model of better, faster heart attack care
6. Redesigned Blue Shield of California Website Makes Finding a Doctor Online Easier and Faster
7. Mental Decline Faster in Brain-Injured Vietnam Vets
8. Cone-Beam CT faster, potentially more accurate than conventional mammography
9. Antidepressants that are more efficient and faster
10. Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments
11. Protein deficiency leads to faster fat burning in mice, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Test May Mean Faster Breast Cancer Treatment
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... Researchers ... is so routine. A fresh look at this technique may yield big benefits. ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of ...
(Date:5/23/2016)... New York, NY (PRWEB) , ... May 23, 2016 , ... ... revolutionary, sport-injury preventative testing program for athletes. This is the first time this type ... South California, is being made available to the public in New York. , With ...
(Date:5/23/2016)... ... 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... September 15 and 16, 2016 in San Diego, CA. The two day summit ... be one of the largest gatherings of medical device companies, suppliers, professionals and experts ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... 23, 2016 , ... Hadley Institute for the Blind and ... blind or visually impaired, announces the election of Julie S. Tye as its ... Board of Trustees retained Morris & Berger, a firm specializing in non-profit executive ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... , May 19, 2016 ... World Congestive Heart Failure (CHF) Treatment Devices Market - ... CHF treatment devices market would reach $14.8 billion by ... 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate ... period. North America is projected ...
(Date:5/19/2016)... 19, 2016 Research ... "Global In-Vitro Diagnostics (IVD) Market Size, Market ... Key Players, Competitive Strategies and Forecasts, 2012 ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... research report forecasts on In-Vitro Diagnostics (IVD) ...
(Date:5/19/2016)...  IBM,s (NYSE:   IBM )  World Community Grid ... drug candidates to cure Zika, a fast spreading virus ... public health emergency. IBM and a global ... or Android device to join the #OpenZika project. Volunteers ... help; they simply  run an app   on ...
Breaking Medicine Technology: